Johnson & Johnson Announces Landmark Phase 3 Results: TECVAYLI® Reduces Risk of Disease Progression or Death by 71% in Early Relapse Multiple Myeloma
Johnson & Johnson (NYSE: JNJ) today announced groundbreaking topline results from the Phase 3 MajesTEC-9 study, demonstrating that TECVAYLI® (teclistamab-cqyv) monotherapy significantly improves outcomes for [Read More…]
